Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,011,824
  • Shares Outstanding, K 54,782
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,000 K
  • EBIT $ -141 M
  • EBITDA $ -141 M
  • 60-Month Beta -0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.51

Options Overview Details

View History
  • Implied Volatility 121.27% (-16.49%)
  • Historical Volatility 54.24%
  • IV Percentile 9%
  • IV Rank 31.03%
  • IV High 321.03% on 09/26/25
  • IV Low 31.38% on 09/08/25
  • Expected Move (DTE 12) 2.25 (12.20%)
  • Put/Call Vol Ratio 3.33
  • Today's Volume 13
  • Volume Avg (30-Day) 167
  • Put/Call OI Ratio 3.04
  • Today's Open Interest 3,355
  • Open Int (30-Day) 2,898
  • Expected Range 16.22 to 20.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.68
  • Low Estimate -0.76
  • Prior Year -0.39
  • Growth Rate Est. (year over year) -84.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.75 +34.33%
on 02/17/26
18.92 -2.38%
on 03/06/26
+3.11 (+20.25%)
since 02/06/26
3-Month
13.75 +34.33%
on 02/17/26
19.68 -6.15%
on 12/11/25
+0.27 (+1.48%)
since 12/05/25
52-Week
7.80 +136.79%
on 05/23/25
19.71 -6.29%
on 10/13/25
+2.72 (+17.27%)
since 03/06/25

Most Recent Stories

More News
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics Announces Proposed Public Offering of Common Stock

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 18.47 (-0.16%)
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 18.47 (-0.16%)
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim...

BCAX : 18.47 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 19.82
2nd Resistance Point 19.37
1st Resistance Point 18.92
Last Price 18.47
1st Support Level 18.02
2nd Support Level 17.57
3rd Support Level 17.12

See More

52-Week High 19.71
Last Price 18.47
Fibonacci 61.8% 15.16
Fibonacci 50% 13.75
Fibonacci 38.2% 12.35
52-Week Low 7.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar